Peregrine Pharmaceuticals  

(Public, NASDAQ:PPHM)   Watch this stock  
Find more results for PPHM
0.360
-0.009 (-2.33%)
Aug 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.36 - 0.37
52 week 0.29 - 1.33
Open 0.37
Vol / Avg. 369,252.00/679,342.00
Mkt cap 86.22M
P/E     -
Div/yield     -
EPS -0.27
Shares 241.46M
Beta 1.25
Inst. own 14%
Sep 7, 2016
Q1 2017 Peregrine Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 14, 2016
Q4 2016 Peregrine Pharmaceuticals Inc Earnings Call
Jul 14, 2016
Q4 2016 Peregrine Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Apr '16) 2016
Net profit margin -63.27% -124.54%
Operating margin -63.44% -126.12%
EBITD margin - -122.69%
Return on average assets -41.80% -53.90%
Return on average equity -94.22% -110.24%
Employees 281 -
CDP Score - -

Address

14282 Franklin Ave
TUSTIN, CA 92780
United States - Map
+1-714-5086000 (Phone)
+1-302-6745266 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. Bavituximab is its lead immunotherapy candidate. Bavituximab is a monoclonal antibody that targets and binds to phosphatidylserine (PS), a immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then flips and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. The Company's subsidiary is Avid Bioservices, Inc. (Avid). Avid provides integrated current good manufacturing practices (cGMP) services from cell line development to commercial biomanufacturing.

Officers and directors

Carlton M. Johnson Jr. Independent Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Steven W. King President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Paul J. Lytle Chief Financial Officer
Age: 47
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark R. Ziebell Vice President, General Counsel, Corporate Secretary
Age: 51
Bio & Compensation  - Reuters
Shelley P.M. Fussey Ph.D. Vice President - Intellectual Property
Age: 49
Bio & Compensation  - Reuters
Joseph S. Shan Vice President - Clinical & Regulatory Affairs
Age: 42
Bio & Compensation  - Reuters
David H. Pohl Independent Director
Age: 78
Bio & Compensation  - Reuters
Eric S. Swartz Independent Director
Age: 59
Bio & Compensation  - Reuters